

Global Leader in Digital  
Pediatric Vision Care Solutions



## IN BRIEF

**2016** Established

**21** Employees

**21** Granted Patents

**2** Approved products

**\$26M** Raised

**2** Global subsidiaries (US, China)

Supported by leading strategic and venture capital

**RIMONCI** 睿盟希

**Santen**


**ESSILORLUXOTTICA**

**TECHNION**  
Israel Institute  
of Technology



# PRODUCT PORTFOLIO

# TECHNOLOGY



## Eye-Tracking



- ✓ IR sensor/future consumer electronics
- ✓ Ocular motility & attention
- ✓ Samples 90 times per second
- ✓ Objective & accurate


## Data Analysis










- ✓ Real time image processing according to momentary eye gaze
- ✓ Diagnosis based on deep ophthalmic knowledge
- ✓ Data collection, AI and norms creation

# CureSight AMBLYOPIA TREATMENT

- ✓ Treatment performed by watching any streamed content at the comfort of home
- ✓ Principle: real time image processing according to the momentary gaze position



IP: Patent granted in US and China (apparatus and method), second pending patent (no eye-tracking) Positive FTO analysis


-  Binocular treatment
-  Clinically proven vs. patching
-  Home treatment
-  Fun and engaging
-  Unlimited variety of streamed content
-  Short treatment period
-  Remote monitored
-  Coverage may apply



# CureSight CLINICAL RESULTS & REGULATION


- ✓ Multi center RCT, 103 subjects
- ✓ Primary endpoint met, better VA improvement than control, significant stereo improvement
- ✓ High **adherence (93%)** and **satisfaction (95%)**
- ✓ FDA cleared and CE marked under MDR
- ✓ **First ever successful pivotal study against gold standard patching**

## Visual Acuity – Amblyopic Eye improvement





### Proportion with ≥ 2 Lines Improvement

Out of the patients who reached the 16-week visit, proportion of patients with amblyopic eye BCVA improvement ≥ 2 lines:




## CLINICAL RESULTS - GAINS STABLE FOR ONE YEAR



# CureSight us LAUNCH STATUS




Trained Prescribers



Patients

- ✓ 650+ referred
- ✓ 87 patients had their first check-up, significant average improvement
- ✓ 550+ claims submitted, 9 approvals on file from different payors (Cigna, UHC, BCBS, etc)

Yearly referral growth forecast



## GLOBAL LAUNCH



### Europe Launch

- ✓ CE mark approved under MDR
- ✓ Distribution agreement signed for Italy
- ✓ 13 active prescribers and 7 referred patients



### China Launch

- ✓ Clinical trial completed successfully
- ✓ NMPA approval expected in Q2 2024
- ✓ Distribution discussions with Fitlens, Zhuhai

## KEY OUTCOMES GOALS

- Global launch of CureSight, including NMPA approval
- Europe launch of EyeSwift<sup>PRO</sup>
- FDA and NMPA approvals of EyeSwift<sup>PRO</sup>
- Next generation CureSight development
- TrackSight successful pilot study and launch as a wellness App
- Two years of runway